LHF-535 is an antiviral agent extracted from patent WO2013123215A2, Compound 38, has EC 50 s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively.
In Vitro
LHF-535 is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein (GP). LHF-535 exhibits potent antiviral activity against a broad array of hemorrhagic fever arenaviruses. LHF-535 inhibits Lassa GP-pseudotyped lentivirus with an IC 50 of 0.1-0.3 nM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
LHF-535 (3, 10 or 30 mg/kg; orally; daily; 14 days) protectes mice from a lethal challenge with Tacaribe virus and dramatically reduces viral titers in plasma, spleen, and liver. An increase in survival is also observed when the first dose of LHF-535 (10 mg/kg) is delayed by 1, 2, or 3 days after infection, demonstrating that LHF-535 is efficacious as a post-exposure therapeutic in mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: IFN-α/β and-γ receptor-deficient AG129 miceDosage: 3, 10, or 30 mg/kg/day Administration: Orally; daily; 14 days Result: Effective as a post-exposure therapeutic.
Form:Solid
